PORTLAND, Ore., May 16, 2016 /PRNewswire/ -- AbSci announced today the appointment of Daniel Gold, Ph.D. to AbSci's Board of Directors. Dr. Gold has served in senior management roles at several leading biotechnology companies and currently serves as Vice President of Process Sciences at BioMarin Pharmaceutical, Inc. (NASDAQ: BMRN).
"Dr. Gold brings over 30 years of experience in the biotech industry as both a scientist and executive. His vast technical expertise in scaling up of industrial fermentation processes along with his understanding of downstream process development will be invaluable for us as we continue to develop our technology," said Sean McClain, Founder and CEO of AbSci. "We are honored to welcome his input and guidance in advancing the commercialization of SoluPro™."
"I am very excited about the opportunity to join AbSci's Board of Directors," said Dr. Gold. "The economical production of complex biologicals remains an unmet need for the biotechnology industry. AbSci's novel SoluPro™ technology provides a means towards this industry-wide goal. I look forward to participating in the development, implementation, and partnering of this major scientific and engineering advancement.
Dr. Gold currently serves as VP of Process Sciences at BioMarin Pharmaceuticals, where he oversees more than 100 employees and is responsible for upstream, downstream, formulation, and analytical development. Previously, he was CEO and President of Sutro Biopharma from 2007 to 2010. Prior to Sutro, Dr. Gold was Senior Vice President of Pharmaceutical Operations at Human Genome Sciences from 2002 to 2006 and served as Vice President and CSO at Covance Biotechnology Services from 1996 to 2002. Earlier in his career, Dr. Gold held scientific and process development roles at Khepri Pharmaceuticals, Genentech, and Genencor.
Dr. Gold holds a B.S. in Chemical Engineering from Tufts University and a M.S. and Ph.D. in Biochemical Engineering from the Massachusetts Institute of Technology.
AbSci is a global leader in protein production technologies. The company's SoluProTM expression platform achieves revolutionary yields of soluble and active protein products. AbSci's unique approach accelerates drug discovery timelines, increases manufacturing efficiencies, and drastically reduces costs for the biopharmaceutical industry. For more information, please visit www.abscibio.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/absci-appoints-daniel-gold-phd-to-board-of-directors-300268795.html